I n their article regarding the timing of adjuvant chemotherapy in patients with colon cancer, Hershman et al. 1 stated that the effect of the interval between surgery and the beginning of adjuvant chemotherapy has not been investigated to date. However, to our knowledge, there are at least 3 publications addressing this question, with somewhat differing results. The first is from Arkenau et al., 2 who conducted a trial of leucovorin and 5-fluorouracil (5-FU) versus levamisole and 5-FU and found a reduced rate of disease recurrence if this interval was <27 days (P ΒΌ .01); at the time of last follow-up, survival was not found to be improved in the group who received early adjuvant treatment. Conversely, in the study by Taal et al. 3 regarding the combination of levamisole and 5-FU, early adjuvant treatment (<4 weeks) did not appear to affect results. In the third study, Chau et al. 4 found a significant survival advantage for patients in whom adjuvant chemotherapy was initiated within 8 weeks of surgery (P ΒΌ .044). This latter finding was confirmed by Hershman et al. in a patient population age >65 years for overall survival, with the first significant increase in the hazards ratio (HR) noted in the 2-month to 3-month interval, whereas disease-specific survival was found to significantly worsen only after an interval of >3 months (HR of 1.5; P < .05). 1 Therefore, as discussed by the authors, related factors and not the tumor or the interval between surgery and chemotherapy itself may be the reason for the worse outcome observed after an interval of 2 to 3 months. Furthermore, other subgroups (such as young patients with high-grade tumors) also should have been studied, because for example in breast cancer, an early start (<21 days) to adjuvant treatment may be indicated for premenopausal patients with receptor-negative tumors. 5 However, an interval of <2 months between surgery and the beginning of adjuvant chemotherapy could be accepted as a preliminary standard for colon cancer.